Liu Ning, Feng Gang, Zhang Xiaoying, Hu Qingjuan, Sun Shiqiang, Sun Jiaqi, Sun Yanan, Wang Ran, Zhang Yan, Wang Pengjie, Li Yixuan
Key Laboratory of Precision Nutrition and Food Quality, Ministry of Education, Department of Nutrition and Health, China Agricultural University, Beijing, China.
Key Laboratory of Functional Dairy, Ministry of Education, Department of Nutrition and Health, China Agricultural University, Beijing, China.
Front Nutr. 2021 Nov 25;8:759507. doi: 10.3389/fnut.2021.759507. eCollection 2021.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is one of the main types of intestinal inflammatory diseases with intestine mucosal immune disorder. Intestine mucosal immune system plays a remarkable and important role in the etiology and pathogenesis of IBD. Therefore, understanding the intestine mucosal immune mechanism is a key step to develop therapeutic interventions for IBD. Intestine mucosal immune system and IBD are influenced by various factors, such as inflammation, gut permeability, gut microbiota, and nutrients. Among these factors, emerging evidence show that nutrients play a key role in inflammation activation, integrity of intestinal barrier, and immune cell modulation. Lactoferrin (LF), an iron-binding glycoprotein belonging to transferrin family, is a dietary bioactive component abundantly found in mammalian milk. Notably, LF has been reported to perform diverse biological functions including antibacterial activity, anti-inflammatory activity, intestinal barrier protection, and immune cell modulation, and is involved in maintaining intestine mucosal immune homeostasis. The improved understanding of the properties of LF in intestine mucosal immune system and IBD will facilitate its application in nutrition, clinical medicine, and health. Herein, this review outlines the recent advancements on LF as a potential therapeutic intervention for IBD associated with intestine mucosal immune system dysfunction. We hope this review will provide a reference for future studies and lay a theoretical foundation for LF-based therapeutic interventions for IBD by understanding the particular effects of LF on intestine mucosal immune system.
炎症性肠病（IBD）包括溃疡性结肠炎（UC）和克罗恩病（CD），是肠道炎症性疾病的主要类型之一，伴有肠道黏膜免疫紊乱。肠道黏膜免疫系统在IBD的病因和发病机制中起着显著且重要的作用。因此，了解肠道黏膜免疫机制是开发IBD治疗干预措施的关键步骤。肠道黏膜免疫系统和IBD受到多种因素的影响，如炎症、肠道通透性、肠道微生物群和营养物质。在这些因素中，新出现的证据表明，营养物质在炎症激活、肠道屏障完整性和免疫细胞调节中起关键作用。乳铁蛋白（LF）是一种属于转铁蛋白家族的铁结合糖蛋白，是在哺乳动物乳汁中大量发现的一种膳食生物活性成分。值得注意的是，据报道LF具有多种生物学功能，包括抗菌活性、抗炎活性、肠道屏障保护和免疫细胞调节，并参与维持肠道黏膜免疫稳态。对LF在肠道黏膜免疫系统和IBD中特性的进一步了解将促进其在营养、临床医学和健康领域的应用。在此，本综述概述了LF作为一种与肠道黏膜免疫系统功能障碍相关的IBD潜在治疗干预措施的最新进展。我们希望本综述能为未来的研究提供参考，并通过了解LF对肠道黏膜免疫系统的特殊作用，为基于LF的IBD治疗干预措施奠定理论基础。
